CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
This article explains why benchmark returns can differ from index returns and what this means for investors evaluating results.
26,521 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
A legal fight over a listing rule has spiraled into concerns about privacy and governance inside the National Associa...
A sweeping 2025 reform repeals long-standing Social Security penalties for public workers, boosting retirement checks...
Boise remains a retirement magnet, but costs have risen. With a $900K pot, a paid-off home, and careful tax and cash-...
Congress passed a sweeping housing package that has now become law, promising to streamline permitting, expand financ...
What happens when mega-stars perform for a cause rather than a paycheck? This article unpacks the no-fee halftime sho...
As job cuts persist in early 2026, employers cite AI adoption to explain restructuring. The trend underscores why wor...
Authorities say 72 tigers died thai zoos in Chiang Mai from canine distemper, not bird flu, easing human health fears...
A Friday deadline intensifies a clash between Anthropic and the Pentagon over how its Claude AI models may be used by...
What the arcturus (arct) 2025 earnings report may reveal isn’t just about a single quarter. This guide breaks down th...
A fresh settlement involving Ticketmaster sparked a rally in Live Nation shares, signaling investor relief but stirri...
Apple rolls out the MacBook Neo at $599 as memory and storage costs surge on AI-driven demand. This piece analyzes me...